Page 5 - Dror Bashan News Today

Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX – Get Rating) – Analysts at Zacks Investment Research issued their Q2 2022 earnings estimates for Protalix BioTherapeutics in a note issued to investors on Tuesday, May 17th. Zacks Investment Research analyst J. Vandermosten forecasts that the company will earn ($0.18) per share for the quarter. Zacks Investment Research also issued […]

Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.

Protalix BioTherapeutics Inc. (NYSE:NYSE:PLX) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Alexandra Schuman - LifeSci Advisors, IR Dror Bashan - President...

Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX – Get Rating) saw a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 5,650,000 shares, an increase of 39.5% from the March 31st total of 4,050,000 shares. Based on an average daily volume of 3,680,000 shares, the short-interest ratio is […]

The positive data from the Phase III BALANCE study is expected to support the resubmission of a Biologics License Application for PRX-102.

/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and...

Protalix BioTherapeutics and Chiesi have reported final data from the Phase III BRIGHT trial of pegunigalsidase alfa for Fabry disease.

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce the Submission of a Marketing Authorization Application to the European Medicines Agency for PRX-102 for the Treatment of Fabry Disease - read this article along with other careers information, tips and advice on BioSpace

/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and...

/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and...